T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis
Authors:
- Martina OrianoMOMartina Oriano
- Andrea GramegnaAGAndrea Gramegna
- Francesco AmatiFAFrancesco Amati
- Alice D’addaADAlice D’adda
- Michele GaffuriMGMichele Gaffuri
- Marco ContoliMCMarco Contoli
- Francesco BindoFBFrancesco Bindo
- Edoardo SimonettaESEdoardo Simonetta
- Carlotta Di FrancescoCFCarlotta Di Francesco
- Martina SantambrogioMSMartina Santambrogio
- Giovanni SotgiuGiovanni Sotgiu
- Francesco BlasiFrancesco Blasi
Open Access
- 2 July 2021
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 9 (7) , 772
Abstract
Although bronchiectasis pathophysiology has been historically understood around the presence of airway neutrophilic inflammation, recent experiences are consistent with the identification of a type 2 inflammation (T2) high endotype in bronchiectasis. In order to evaluate prevalence and clinical characteristics of bronchiectasis patients with a T2-high endotype and explore their response to biologicals, two studies were carried out. In a cross-sectional study, bronchiectasis adults without asthma underwent clinical, radiological, and microbiological assessment, along with blood eosinophils and oral fractional exhaled nitric oxide (FeNO) evaluation, during stable state. Prevalence and characteristics of patients with a T2- high endotype (defined by the presence of either eosinophils blood count ≥300 cells·µL−1 or oral FeNO ≥ 25 dpp) were reported. A case series of severe asthmatic patients with concomitant bronchiectasis treated with either mepolizumab or benralizumab was evaluated, and patients’ clinical data pre- and post-treatment were analyzed up to 2 years of follow up. Among bronchiectasis patients without asthma enrolled in the cross-sectional study, a T2-high endotype was present in 31% of them. These patients exhibited a more severe disease, high dyspnea severity, low respiratory function, and high impact on quality of life. Among the five patients with severe eosinophilic asthma and concomitant bronchiectasis included in the series, treatment with either mepolizumab or benralizumab significantly reduced the exacerbation rate with an effect that persists for up to 2 years of follow up. If validated across different settings, our data suggest the need to design randomized controlled trials on biological treatments targeting the T2-high endotype in bronchiectasis patients.Keywords
This publication has 36 references indexed in Scilit:
- Etiology of Non–Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease SeverityAnnals of the American Thoracic Society, 2015
- Biomarkers to identify sputum eosinophilia in different adult asthma phenotypesEuropean Respiratory Journal, 2015
- Targeting Immune Pathways for Therapy in Asthma and Chronic Obstructive Pulmonary DiseaseAnnals of the American Thoracic Society, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- The Bronchiectasis Severity Index. An International Derivation and Validation StudyAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasisRespirology, 2013
- Short- and Long-Term Antibiotic Treatment Reduces Airway and Systemic Inflammation in Non–Cystic Fibrosis BronchiectasisAmerican Journal of Respiratory and Critical Care Medicine, 2012
- An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (F e NO) for Clinical ApplicationsAmerican Journal of Respiratory and Critical Care Medicine, 2011
- An Investigation into Causative Factors in Patients with BronchiectasisAmerican Journal of Respiratory and Critical Care Medicine, 2000
- CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types.American Journal of Roentgenology, 1995